Wire · opportunities
A new strategy for secondary stroke prevention gets boost from FDA approval
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 11 November 2026 · Fusion42 review
The FDA approved Sunharbo (asundexian), a first-in-class Factor XI inhibitor, to reduce the risk of secondary ischemic stroke by 26% without increasing major bleeding risks. The drug is intended for adults with mild-to-moderate noncardioembolic stroke or high-risk transient ischemic attack (TIA) and is to be used alongside antiplatelet therapy.
This Wire brief sits within Fusion42's coverage of Medtech, and 15 sources have reported it between 9 Nov 2026 and 19 Nov 2026.
◆ ◆ The Wire takeaway
Your stroke treatment options just expanded with a drug that lowers risk without raising bleeding. If you work in Medtech or healthcare, buyers and patients will expect safer secondary stroke therapies this year.
◆ Coverage
15 sources · first reported 9 Nov 2026 · latest 19 Nov 2026
◆ Related on Wire
◆ Topics